R&D | Cutting-edge science and innovative research

News

PepGen slumps as FDA places hold on lead drug

Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.

News

Can GLP-1 drugs help tackle addiction?

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

News

Welsh firm Antiverse raises funds for AI antibody platform

Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.

News

Five projects share £100m UK-US Cancer Grand Challenges fund

Five scientific teams will receive up to £20m each in a new round of funding under the UK and US Cancer Grand Challenges initiative.

News

Moderna agrees $950m settlement of mRNA jab litigation

Moderna's settlement of patent litigation with Arbutus and Genevant over technology used in its Spikevax COVID vaccine could reach up to $2.25bn.

R&D

This week in clinical trials: 8th-12th January

In our second clinical trials update of 2024, taking in developments in life sciences research and development from early-stage onwards, we look at a wide range of announcements – from onco

R&D

JP Morgan 2024 – Jeff Smith

Editor-in-chief Jonah Comstock sat down with Jeff Smith, chief research officer at Precision BioSciences, on the side lines of the JP Morgan Healthcare Conference in San Francisco to discus

R&D

Partner Content

Measuring Patient Engagement Summit

Quantifying the Success of Your Patient Engagement Activities to Satisfy Regulatory Requirements, Present ROI to Stakeholders, and Above All Improve the Patient Experience

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

PepGen slumps as FDA places hold on lead drug

Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.

News

Can GLP-1 drugs help tackle addiction?

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Clinical trials, various research areas, concept

Clinical Trials Round-Up – Jan to Feb 2026

Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.

R&D

pharmaphorum podcast Episode 248, Andrew McKinnon, Medable

AI in clinical development & ‘white space’, with Andrew McKi...

Andrew McKinnon, senior vice president and executive general manager at Medable, discussesleveraging AI to transform & accelerate clinical development

R&D

Rare disease at an inflection point: Why the next wave will ...

As rare disease becomes more competitive, information parity is disappearing.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

AI in clinical development & ‘white space’, with Andrew McKi...

Andrew McKinnon, senior vice president and executive general manager at Medable, discussesleveraging AI to transform & accelerate clinical development

R&D

JPM2026 wrap-up with Nicole Raleigh and Jonah Comstock

On JPM2026 and healthcare investment today, with Jonah Comst...

Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.

R&D

pharmaphorum podcast Episode 239, Dr Jorg Schuttrumpf

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

Video

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D

Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

R&D

Life Sciences Industry Report - Rare Disease Space

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

Event

Partner Content

7th Dermatology Drug Development Summit Europe

The Summit is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists

R&D

Partner Content

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals

Partner Content

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam

Partner Content

Event

Partner Content

7th Dermatology Drug Development Summit Europe

The Summit is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists

R&D

Partner Content

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals

Partner Content

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam

PepGen slumps as FDA places hold on lead drug

Can GLP-1 drugs help tackle addiction?

Welsh firm Antiverse raises funds for AI antibody platform

Five projects share £100m UK-US Cancer Grand Challenges fund

Moderna agrees $950m settlement of mRNA jab litigation

This week in clinical trials: 8th-12th January

JP Morgan 2024 – Jeff Smith

Measuring Patient Engagement Summit

Synthetic control arms in clinical trials: Making it happen

How synthetic control arms are changing clinical trials

PepGen slumps as FDA places hold on lead drug

Can GLP-1 drugs help tackle addiction?

Touring Chiesi's vision for the future at the new Biotech Ce...

Vir awarded $1 billion multi-year BARDA influenza contract

Clinical Trials Round-Up – Jan to Feb 2026

AI in clinical development & ‘white space’, with Andrew McKi...

Rare disease at an inflection point: Why the next wave will ...

The GLP-1 Reckoning

Designing obesity trials around real lives: How patient cent...

Beyond obesity: How GLP-1s are changing the game for hundred...

Exploring the future: Opportunities and challenges in cell a...

Beyond clinical: Boosting recruitment and retention with SDO...

The evolution of clinical research: Embracing new delivery m...

AI in clinical development & ‘white space’, with Andrew McKi...

On JPM2026 and healthcare investment today, with Jonah Comst...

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

The long-delayed promise of the microbiome, with Sam Possemi...

Allogeneic cell therapy isn’t dead, with Brian Culley

A New Framework to Engineer Breakthrough Value for Medicines

Life Sciences Industry Report - Biologics and Generics

Life Sciences Industry Report - Rare Disease Space

7th Dermatology Drug Development Summit Europe

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

7th Dermatology Drug Development Summit Europe

Emerging Trends in Personalised Medicine at PHARMAP 2026

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

Lilly unveils employer scheme for weight-loss drug Zepbound

Using AI-driven synthetic personas to take your insights fur...

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Editor's Picks